Revive Therapeutics Ltd

Research Revive Therapeutics Ltd (31R) on Bullrun: market cap EUR 3.27M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker31R
• ExchangeF
• CountryCanada
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Market capEUR 3.27M
• Financial periodQ4 2025
• Net income-EUR 238.73K
• Free cash flow-EUR 8.07K

Valuation Snapshot

latest market cap is EUR 3.27M.

About Revive Therapeutics Ltd

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

Frequently asked questions

What is Revive Therapeutics Ltd's market cap?

Revive Therapeutics Ltd's market capitalization is EUR 3.27M.

What does Revive Therapeutics Ltd do?

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders.